アブストラクト
| Title | 薬剤師が考える免疫関連有害事象 (irAE) マネジメント |
|---|---|
| Subtitle | 総説 |
| Authors | 藤堂真紀 |
| Authors (kana) | |
| Organization | 埼玉医科大学国際医療センター薬剤部 |
| Journal | 日本臨床腫瘍薬学会雑誌 |
| Volume | 18 |
| Number | |
| Page | 8-13 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | 日本臨床腫瘍薬学会 |
| Abstract | [POINT] ・irAEに薬剤師はどう対応するか ・irAE発生後の管理 ・複合免疫療法への対応 「irAEに薬剤師はどう対応するか」免疫チェックポイント阻害薬が様々ながん種に適応となり, もはや, がん薬物療法の主流であると言っても過言ではない. 免疫チェックポイント阻害薬による免疫関連有害事象(immune-related adverse events: irAE)の発症は一定の頻度で認められ, 発症を契機に, 日常生活動作の低下を来したり, 重症例では死亡に至ったりする場合もある. 一方で, irAEは, 抗腫瘍効果と併存するようにして発生することが知られており, 免疫チェックポイント阻害薬により長期生存を得る可能性を有する症例の治療を継続するという意味でも, irAEマネジメントは重要である. irAEマネジメントにおける薬剤師の役割については, 米国の薬剤師の総説をもとに薬剤師の役割の概要を図1にまとめた. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Medina P, Jeffers KD, Trinh VA, Harvey RD:The role of pharmacists in managing adverse events related to immune checkpoint inhibitor therapy, J Pharm Pract 2020;33(3):338-349.
- 2) Le S, Chang B, Pham A, Chan A:Impact of pharmacist-managed immune checkpoint inhibitor toxicities, J Oncol Pharm Pract 2020;6:1078155220928407.
- 3) Renna CE, Dow EN, Bergsbaken JJ, Leal TA:Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities, J Oncol Pharm Pract 2019;25(4):954-960.
- 4) 日本臨床腫瘍学会:がん免疫療法ガイドライン第2版:金原出版, 2019年3月.
- 5) Postow MA, Sidlow R, Hellmann MD:Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med 2018;378(2):158-168.
残りの15件を表示する
- 6) Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB:Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and Meta-analysis, JAMA Oncol 2018;4(12):1721-1728.
- 7) Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M:Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan, Neurology 2017;89(11):1127-1134.
- 8) Khoja L, Day D, Chen TW, Siu LL, Hansen AR:Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:A systematic review, Ann Oncol 2017;28(10):2377-2385.
- 9) Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD:Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib, Ann Oncol 2019;30(5):839-844.
- 10) Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F:Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity, Circulation 2017;136(21):2085-2087.
- 11) Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T;consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research:Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy, Diabetol Int 2018;10(1):58-66.
- 12) Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA;National Comprehensive Cancer Network:ASCO management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol 2018;36(17):1714-1768.
- 13) National Comprehensive Cancer Network:NCCN clinical practice guidelines in oncology (NCCN Guidelines(R)):Management of immunotherapy-related toxicities, 2019.
- 14) Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, Angelo SD, Woo KM:Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol 2015;33(28):3193-3198.
- 15) Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks L, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD:Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer, J Clin Oncol 2018;36(28):2872-2878.
- 16) Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, Basset-Seguin N, Viguier M, Madjlessi-EzrA N, Schneider P, Bagot M, Resche-Rigon M, Lebbe C:Nika Madjlessi-EzrA, Pierre Schneider, Martine Bagot, Matthieu Resche-Rigon, Celeste Lebbe:Single-center study under a french temporary authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma:Negative impact of baseline corticosteroids, Eur J Dermatol 2015;25(1):36-44.
- 17) Scott SC, Pennell NA:Early Use of Systemic Corticosteroids in patients with advanced NSCLC treated with nivolumab, J Thorac Oncol 2018;13(11):1771-1775.
- 18) National Comprehensive Cancer Network:NCCN clinical practice guidelines in oncology (NCCN Guidelines(R)):antiemesis, 2020.
- 19) Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Beauregard MB, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F:Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease, J Crohn's Colitis 2016;10(4):395-401.
- 20) 各務博 監修. チームで取り組む免疫チェックポイント阻害薬治療. 2019;中外医学社.
